Summary
We're thrilled to share the exciting news of launching our inaugural affiliate in the UK! Our decision to expand into the UK is driven by multiple factors:
Over recent years, we've observed that the UK, despite Brexit, continues to be a highly appealing destination for medical research.
With world-renowned centers of medical innovation like University of Cambridge and University of Oxford, many of our clients are either based in the UK or have significant operations there.
At iliomad Health Data , our mission is to support our clients in the best possible locations, and the UK certainly provides an excellent setting for this.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
Safety Reporting Personal Data in Clinical Trials: GDPR Obligations and Cross-Border Risks
Understand GDPR obligations for safety reporting personal data in clinical trials, including adverse event disclosure timelines, cross-border transfer rules and sponsor duties.
Weekly Digest: Healthcare Cyber Breaches, AI Regulation Advances and Genetic Data Enforcement | iliomad
Ransomware mortality data, the FDA-EMA AI framework, Germany's KI-MIG, the EU-US DPF under review and a wave of US healthcare breaches: this week's digest for biotech and healthtech.
EU Digital Omnibus Simplifies AI Act Obligations; Rhode Island Enacts AI Healthcare Laws
Regulation (EU) 2026/1744 streamlines EU AI Act compliance, while Rhode Island enacts three AI healthcare laws. Key updates for biotech and healthtech teams.
